20% of COVID-19 patients will contract acute respiratory distress syndrome (ARDS). The BBC report actually states that in the case of SARS and MERS between 20% to 60% of patients experienced symptoms consistent with pulmonary fibrosis. a substantial proportion of patients who develop ARDS and survive the acute phase of the illness die as a result of progressive pulmonary fibrosis.'
1AD had achieved two important milestones, yet the market is slow to catch up, after FDA supportive milestone, today 1AD anns:
23 July 2020 ASX Announcement FIRST PARTICIPANTS TREATED IN AD-214 PHASE I CLINICAL TRIAL MELBOURNE Australia, 23 July 2020: AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform is pleased to announce that the first healthy participants in the blinded Phase I clinical trial of AD-214 have been treated. One participant received AD-214 and one received placebo. Both participants have passed the 72-hour observation window without a dose limiting adverse event (DLAE). CEO and Managing Director Dr Tim Oldham said, “We are pleased to have achieved this next important milestone in the initial clinical evaluation of AD-214. We also wish to express our gratitude to the volunteers who have agreed to participate in this trial and help advance a potential new therapy for patients battling interstitial lung disease, beginning with idiopathic pulmonary fibrosis.”
This shall rocket up to 20 cents given the solid progress the company is making.
